RxDoctor Payments Data

Juanquetta Howell

Family · Millsboro, DENPI 1336512201

Payments from drug & device makers

$1,060in general payments, 2019–2025

Across 54 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$292
  • AstraZeneca$220
  • Astellas Pharma US Inc$122
  • Exact Sciences$90
  • Pfizer$62
  • AbbVie$56
  • plus $219 from 8 others

What the payments were for

  • Food & beverage$98593%
  • Education$757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,060 in reported general payments places this provider in the 65th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$37,606
Medicare patients
180
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$53,715
JardianceEmpagliflozin25$25,845
TrulicityDulaglutide14$20,906
RybelsusSemaglutide13$18,865
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,839
FarxigaDapagliflozin Propanediol12$13,518
EliquisApixaban11$8,871
Breo ElliptaFluticasone/Vilanterol15$7,655
Albuterol Sulfate HfaAlbuterol Sulfate74$1,821
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,691
Atorvastatin Calcium221$1,612
Rosuvastatin Calcium78$1,519
Levothyroxine Sodium118$1,175
Gabapentin77$1,142
Omeprazole92$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$292$72,58036 claims
Lilly USA, LLCTrulicity$48$20,90614 claims
AstraZenecaFarxiga$220$13,51812 claims
PfizerEliquis$62$8,87111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 523 family providers in Delaware.

Other family in Millsboro

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →